Chemicals & Advanced Materials Global On demand · 24-48h

Global Cannabinol (CBN) Market Strategic Research Report

Global Cannabinol (CBN) Market Strategic Research Report
$3,500 USD
Market Research Reports
Strategic Research Report
Global Cannabinol (CBN) Market
$4382025
9.3%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: CBN Isolate, CBN Distillate

By Application: Supplements, Food and Beverages, Cosmetics, Pharmaceuticals

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: GVB Biopharma, Enecta, Pharma Works LLC (CanniLabs), Red Mesa Science & Refining, LLC, KND Labs, Planta Scientific, Fresh Bros Hemp Company, Green Exchange, Ag Marvels, Extract Labs, Ilesol Pharmaceuticals, WeeDutch, Mile High Labs, Essentia Pura, Northeast Heritage Limited, Blue Sky Hemp Ventures Hemp Ventures, Verus Extracts, EcoGen Biosciences, Sequoya

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 143 pages
Market size 2025
$438
Million USD
Forecast CAGR
9.3%
2025-2032
Forecast 2032
$816.2
Projected
영역들
5
Asia Pacific · Latin America · MEA · Europe · North America

개요

Scope of the Report

The global Cannabinol (CBN) market size is predicted to grow from US$ 438 million in 2025 to US$ 805 million in 2032; it is expected to grow at a CAGR of 9.3% from 2026 to 2032.

CBN can be understood as a weaker version of THC. When THC components found in the cannabis plant age, they break down. This leads to the formation of a less potent cannabinoid called CBN. It’s about 25% as effective as THC, which makes it a mild chemical.Unlike CBD, which is entirely non-psychoactive, CBN in larger doses can produce mild psychoactive reactions.

Global key Cannabinol (CBN) players cover GVB Biopharma, Enecta, Pharma Works LLC (CanniLabs), Red Mesa Science & Refining, LLC, KND Labs, etc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Cannabinol (CBN) market?

What factors are driving Cannabinol (CBN) market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Cannabinol (CBN) market opportunities vary by end market size?

How does Cannabinol (CBN) break out by Type, by Application?

This report presents a comprehensive overview of the global Cannabinol (CBN) market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • CBN Isolate
  • CBN Distillate

Segment by Application

  • Supplements
  • Food and Beverages
  • Cosmetics
  • Pharmaceuticals

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Cannabinol (CBN) market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Supplements, Food and Beverages, Cosmetics evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Cannabinol (CBN) Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 9.3%
Regional growth momentum
Market share by segment
Key metrics
Base value
$438
2025
Forecast
$816.2
2032
CAGR
9.3%
2025–2032
영역들
5
global
Key companies
GVB BiopharmaEnectaPharma Works LLC (CanniLabs)Red Mesa Science & Refining, LLCKND LabsPlanta ScientificFresh Bros Hemp CompanyGreen Exchange
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
CBN IsolateCBN Distillate
By Application
SupplementsFood and BeveragesCosmeticsPharmaceuticals

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 CBN Isolate
  • 3.1.3 CBN Distillate
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Supplements
  • 4.1.3 Food and Beverages
  • 4.1.4 Cosmetics
  • 4.1.5 Pharmaceuticals
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 GVB Biopharma
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Enecta
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Pharma Works LLC (CanniLabs)
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Red Mesa Science & Refining, LLC
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 KND Labs
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Planta Scientific
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Fresh Bros Hemp Company
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Green Exchange
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Ag Marvels
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Extract Labs
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Ilesol Pharmaceuticals
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 WeeDutch
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Mile High Labs
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Essentia Pura
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Northeast Heritage Limited
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Blue Sky Hemp Ventures Hemp Ventures
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Verus Extracts
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 EcoGen Biosciences
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 Sequoya
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Cannabinol (CBN) market?
The global Cannabinol (CBN) market is estimated at US$ 438 million in 2025 (base year) and is projected to reach US$ 805 million by 2032.
What is the forecast CAGR for the Cannabinol (CBN) market?
The market is expected to grow at a CAGR of 9.3% from 2026 to 2032, expanding from US$ 438 million in 2025 to US$ 805 million in 2032, roughly 1.8 times its base-year value.
What is Cannabinol (CBN)?
CBN can be understood as a weaker version of THC. When THC components found in the cannabis plant age, they break down. This leads to the formation of a less potent cannabinoid called CBN.
What are the main segments of the Cannabinol (CBN) market by type?
By type, the market is segmented into CBN Isolate and CBN Distillate.
Which applications drive demand in the Cannabinol (CBN) market?
Key applications covered include Supplements, Food and Beverages, Cosmetics and Pharmaceuticals.
Who are the key players in the Cannabinol (CBN) market?
Key players profiled include GVB Biopharma, Enecta, Pharma Works LLC (CanniLabs), Red Mesa Science & Refining, KND Labs, Planta Scientific, Fresh Bros Hemp Company and Green Exchange, among 19 companies covered in total.
Which regions and countries are covered for Cannabinol (CBN)?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Cannabinol (CBN) market?
What factors are driving Cannabinol (CBN) market growth, globally and by region?
Who should buy the Cannabinol (CBN) market report?
The report is intended for manufacturers and solution providers, distributors and end users in Supplements, Food and Beverages and Cosmetics, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Cannabinol (CBN) market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from US$3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.